Anticoagulant effect of Huisheng Oral Solution in a rat model of thrombosis

The aim of this study was to investigate whether Huisheng Oral Solution has an anticoagulant effect in a rat model of thrombosis. Forty male SD rats were equally and randomly divided into four groups: blank group, model group, and two treatment groups (A and B). Rats were subcutaneously injected with carrageenan to induce thrombosis. Rats in treatment group A were intragastrically administered with Huisheng Oral Solution in a dose of 2 mL/100 g body weight (once per 8 h) 72 h after carrageenan injection, and those in treatment group B both 72 h before and after the induction of thrombosis. Blood samples were collected 24, 48, and 72 h after carrageenan injection for measurements of prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR), fibrinogen (FIB), prothrombin activity (PTA), platelets (PLT), fibrin degradation products (FDPs), and D-dimer. Lung, liver and mesentery samples were taken 72 h after carrageenan injection for histopathological analysis. The number of microthrombi in sections of different tissue samples were counted under a microscope. Blood parameters among each group were compared using the Welch test, Kruskal-Wallis test or SNK test after testing for normality, while the number of microthrombi was compared using the Bonferroni test. Compared to the model group, PT, APTT, INR, and FIB levels at the majority of time points were significantly shorter or lower in the two treatment groups (P <0.05 for all), but the PTA was not significantly improved in the treatment groups. The levels of FDPs and D-dimer and PLT counts at the majority of time points were significantly lower (P <0.05 for all), and the numbers of microthrombi in the lung, liver and mesentery samples were significantly decreased (P <0.05 for all) in the two treatment groups. The above parameters at the majority of time points showed no significant differences between the two treatment groups. We conclude that Huisheng Oral Solution can significantly improve coagulation parameters, fibrinolysis parameters, and PLT count, and reduce blood hypercoagulability and microthrombosis suggesting that Huisheng Oral Solution has an anticoagulant effect in a rat model of thrombosis. Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Liu Shuang-Qing [verfasserIn] Guo Jiang-Ying [verfasserIn] Deng Qun [verfasserIn] He Zhong-Jie [verfasserIn] Lei Shu-Hong [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2013

Schlagwörter:	Huisheng Oral Solution hypercoagulable state microthrombus fibrinolysis thrombosis

Übergeordnetes Werk:	In: Archives of Biological Sciences - University of Belgrade, University of Novi Sad, 2010, 65(2013), 3, Seite 1223-1231
Übergeordnetes Werk:	volume:65 ; year:2013 ; number:3 ; pages:1223-1231

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.2298/ABS1303223L

Katalog-ID:	DOAJ027291898

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ027291898
003	DE-627
005	20230307112801.0
007	cr uuu---uuuuu
008	230226s2013 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.2298/ABS1303223L \|2 doi
035			\|a (DE-627)DOAJ027291898
035			\|a (DE-599)DOAJcffd23ed4a7547d58c2cebf86370e18c
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a QH301-705.5
100	0		\|a Liu Shuang-Qing \|e verfasserin \|4 aut
245	1	0	\|a Anticoagulant effect of Huisheng Oral Solution in a rat model of thrombosis
264		1	\|c 2013
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a The aim of this study was to investigate whether Huisheng Oral Solution has an anticoagulant effect in a rat model of thrombosis. Forty male SD rats were equally and randomly divided into four groups: blank group, model group, and two treatment groups (A and B). Rats were subcutaneously injected with carrageenan to induce thrombosis. Rats in treatment group A were intragastrically administered with Huisheng Oral Solution in a dose of 2 mL/100 g body weight (once per 8 h) 72 h after carrageenan injection, and those in treatment group B both 72 h before and after the induction of thrombosis. Blood samples were collected 24, 48, and 72 h after carrageenan injection for measurements of prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR), fibrinogen (FIB), prothrombin activity (PTA), platelets (PLT), fibrin degradation products (FDPs), and D-dimer. Lung, liver and mesentery samples were taken 72 h after carrageenan injection for histopathological analysis. The number of microthrombi in sections of different tissue samples were counted under a microscope. Blood parameters among each group were compared using the Welch test, Kruskal-Wallis test or SNK test after testing for normality, while the number of microthrombi was compared using the Bonferroni test. Compared to the model group, PT, APTT, INR, and FIB levels at the majority of time points were significantly shorter or lower in the two treatment groups (P <0.05 for all), but the PTA was not significantly improved in the treatment groups. The levels of FDPs and D-dimer and PLT counts at the majority of time points were significantly lower (P <0.05 for all), and the numbers of microthrombi in the lung, liver and mesentery samples were significantly decreased (P <0.05 for all) in the two treatment groups. The above parameters at the majority of time points showed no significant differences between the two treatment groups. We conclude that Huisheng Oral Solution can significantly improve coagulation parameters, fibrinolysis parameters, and PLT count, and reduce blood hypercoagulability and microthrombosis suggesting that Huisheng Oral Solution has an anticoagulant effect in a rat model of thrombosis.
650		4	\|a Huisheng Oral Solution
650		4	\|a hypercoagulable state
650		4	\|a microthrombus
650		4	\|a fibrinolysis
650		4	\|a thrombosis
653		0	\|a Biology (General)
700	0		\|a Guo Jiang-Ying \|e verfasserin \|4 aut
700	0		\|a Deng Qun \|e verfasserin \|4 aut
700	0		\|a He Zhong-Jie \|e verfasserin \|4 aut
700	0		\|a Lei Shu-Hong \|e verfasserin \|4 aut
773	0	8	\|i In \|t Archives of Biological Sciences \|d University of Belgrade, University of Novi Sad, 2010 \|g 65(2013), 3, Seite 1223-1231 \|w (DE-627)538998008 \|w (DE-600)2380842-1 \|x 18214339 \|7 nnns
773	1	8	\|g volume:65 \|g year:2013 \|g number:3 \|g pages:1223-1231
856	4	0	\|u https://doi.org/10.2298/ABS1303223L \|z kostenfrei
856	4	0	\|u https://doaj.org/article/cffd23ed4a7547d58c2cebf86370e18c \|z kostenfrei
856	4	0	\|u http://www.doiserbia.nb.rs/img/doi/0354-4664/2013/0354-46641303223L.pdf \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/0354-4664 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1821-4339 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 65 \|j 2013 \|e 3 \|h 1223-1231

Indexfelder

author_variant	l s q lsq g j y gjy d q dq h z j hzj l s h lsh
matchkey_str	article:18214339:2013----::nioglnefcohihnoasltoiaam
hierarchy_sort_str	2013
callnumber-subject-code	QH
publishDate	2013
allfields	10.2298/ABS1303223L doi (DE-627)DOAJ027291898 (DE-599)DOAJcffd23ed4a7547d58c2cebf86370e18c DE-627 ger DE-627 rakwb eng QH301-705.5 Liu Shuang-Qing verfasserin aut Anticoagulant effect of Huisheng Oral Solution in a rat model of thrombosis 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The aim of this study was to investigate whether Huisheng Oral Solution has an anticoagulant effect in a rat model of thrombosis. Forty male SD rats were equally and randomly divided into four groups: blank group, model group, and two treatment groups (A and B). Rats were subcutaneously injected with carrageenan to induce thrombosis. Rats in treatment group A were intragastrically administered with Huisheng Oral Solution in a dose of 2 mL/100 g body weight (once per 8 h) 72 h after carrageenan injection, and those in treatment group B both 72 h before and after the induction of thrombosis. Blood samples were collected 24, 48, and 72 h after carrageenan injection for measurements of prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR), fibrinogen (FIB), prothrombin activity (PTA), platelets (PLT), fibrin degradation products (FDPs), and D-dimer. Lung, liver and mesentery samples were taken 72 h after carrageenan injection for histopathological analysis. The number of microthrombi in sections of different tissue samples were counted under a microscope. Blood parameters among each group were compared using the Welch test, Kruskal-Wallis test or SNK test after testing for normality, while the number of microthrombi was compared using the Bonferroni test. Compared to the model group, PT, APTT, INR, and FIB levels at the majority of time points were significantly shorter or lower in the two treatment groups (P <0.05 for all), but the PTA was not significantly improved in the treatment groups. The levels of FDPs and D-dimer and PLT counts at the majority of time points were significantly lower (P <0.05 for all), and the numbers of microthrombi in the lung, liver and mesentery samples were significantly decreased (P <0.05 for all) in the two treatment groups. The above parameters at the majority of time points showed no significant differences between the two treatment groups. We conclude that Huisheng Oral Solution can significantly improve coagulation parameters, fibrinolysis parameters, and PLT count, and reduce blood hypercoagulability and microthrombosis suggesting that Huisheng Oral Solution has an anticoagulant effect in a rat model of thrombosis. Huisheng Oral Solution hypercoagulable state microthrombus fibrinolysis thrombosis Biology (General) Guo Jiang-Ying verfasserin aut Deng Qun verfasserin aut He Zhong-Jie verfasserin aut Lei Shu-Hong verfasserin aut In Archives of Biological Sciences University of Belgrade, University of Novi Sad, 2010 65(2013), 3, Seite 1223-1231 (DE-627)538998008 (DE-600)2380842-1 18214339 nnns volume:65 year:2013 number:3 pages:1223-1231 https://doi.org/10.2298/ABS1303223L kostenfrei https://doaj.org/article/cffd23ed4a7547d58c2cebf86370e18c kostenfrei http://www.doiserbia.nb.rs/img/doi/0354-4664/2013/0354-46641303223L.pdf kostenfrei https://doaj.org/toc/0354-4664 Journal toc kostenfrei https://doaj.org/toc/1821-4339 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 65 2013 3 1223-1231
spelling	10.2298/ABS1303223L doi (DE-627)DOAJ027291898 (DE-599)DOAJcffd23ed4a7547d58c2cebf86370e18c DE-627 ger DE-627 rakwb eng QH301-705.5 Liu Shuang-Qing verfasserin aut Anticoagulant effect of Huisheng Oral Solution in a rat model of thrombosis 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The aim of this study was to investigate whether Huisheng Oral Solution has an anticoagulant effect in a rat model of thrombosis. Forty male SD rats were equally and randomly divided into four groups: blank group, model group, and two treatment groups (A and B). Rats were subcutaneously injected with carrageenan to induce thrombosis. Rats in treatment group A were intragastrically administered with Huisheng Oral Solution in a dose of 2 mL/100 g body weight (once per 8 h) 72 h after carrageenan injection, and those in treatment group B both 72 h before and after the induction of thrombosis. Blood samples were collected 24, 48, and 72 h after carrageenan injection for measurements of prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR), fibrinogen (FIB), prothrombin activity (PTA), platelets (PLT), fibrin degradation products (FDPs), and D-dimer. Lung, liver and mesentery samples were taken 72 h after carrageenan injection for histopathological analysis. The number of microthrombi in sections of different tissue samples were counted under a microscope. Blood parameters among each group were compared using the Welch test, Kruskal-Wallis test or SNK test after testing for normality, while the number of microthrombi was compared using the Bonferroni test. Compared to the model group, PT, APTT, INR, and FIB levels at the majority of time points were significantly shorter or lower in the two treatment groups (P <0.05 for all), but the PTA was not significantly improved in the treatment groups. The levels of FDPs and D-dimer and PLT counts at the majority of time points were significantly lower (P <0.05 for all), and the numbers of microthrombi in the lung, liver and mesentery samples were significantly decreased (P <0.05 for all) in the two treatment groups. The above parameters at the majority of time points showed no significant differences between the two treatment groups. We conclude that Huisheng Oral Solution can significantly improve coagulation parameters, fibrinolysis parameters, and PLT count, and reduce blood hypercoagulability and microthrombosis suggesting that Huisheng Oral Solution has an anticoagulant effect in a rat model of thrombosis. Huisheng Oral Solution hypercoagulable state microthrombus fibrinolysis thrombosis Biology (General) Guo Jiang-Ying verfasserin aut Deng Qun verfasserin aut He Zhong-Jie verfasserin aut Lei Shu-Hong verfasserin aut In Archives of Biological Sciences University of Belgrade, University of Novi Sad, 2010 65(2013), 3, Seite 1223-1231 (DE-627)538998008 (DE-600)2380842-1 18214339 nnns volume:65 year:2013 number:3 pages:1223-1231 https://doi.org/10.2298/ABS1303223L kostenfrei https://doaj.org/article/cffd23ed4a7547d58c2cebf86370e18c kostenfrei http://www.doiserbia.nb.rs/img/doi/0354-4664/2013/0354-46641303223L.pdf kostenfrei https://doaj.org/toc/0354-4664 Journal toc kostenfrei https://doaj.org/toc/1821-4339 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 65 2013 3 1223-1231
allfields_unstemmed	10.2298/ABS1303223L doi (DE-627)DOAJ027291898 (DE-599)DOAJcffd23ed4a7547d58c2cebf86370e18c DE-627 ger DE-627 rakwb eng QH301-705.5 Liu Shuang-Qing verfasserin aut Anticoagulant effect of Huisheng Oral Solution in a rat model of thrombosis 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The aim of this study was to investigate whether Huisheng Oral Solution has an anticoagulant effect in a rat model of thrombosis. Forty male SD rats were equally and randomly divided into four groups: blank group, model group, and two treatment groups (A and B). Rats were subcutaneously injected with carrageenan to induce thrombosis. Rats in treatment group A were intragastrically administered with Huisheng Oral Solution in a dose of 2 mL/100 g body weight (once per 8 h) 72 h after carrageenan injection, and those in treatment group B both 72 h before and after the induction of thrombosis. Blood samples were collected 24, 48, and 72 h after carrageenan injection for measurements of prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR), fibrinogen (FIB), prothrombin activity (PTA), platelets (PLT), fibrin degradation products (FDPs), and D-dimer. Lung, liver and mesentery samples were taken 72 h after carrageenan injection for histopathological analysis. The number of microthrombi in sections of different tissue samples were counted under a microscope. Blood parameters among each group were compared using the Welch test, Kruskal-Wallis test or SNK test after testing for normality, while the number of microthrombi was compared using the Bonferroni test. Compared to the model group, PT, APTT, INR, and FIB levels at the majority of time points were significantly shorter or lower in the two treatment groups (P <0.05 for all), but the PTA was not significantly improved in the treatment groups. The levels of FDPs and D-dimer and PLT counts at the majority of time points were significantly lower (P <0.05 for all), and the numbers of microthrombi in the lung, liver and mesentery samples were significantly decreased (P <0.05 for all) in the two treatment groups. The above parameters at the majority of time points showed no significant differences between the two treatment groups. We conclude that Huisheng Oral Solution can significantly improve coagulation parameters, fibrinolysis parameters, and PLT count, and reduce blood hypercoagulability and microthrombosis suggesting that Huisheng Oral Solution has an anticoagulant effect in a rat model of thrombosis. Huisheng Oral Solution hypercoagulable state microthrombus fibrinolysis thrombosis Biology (General) Guo Jiang-Ying verfasserin aut Deng Qun verfasserin aut He Zhong-Jie verfasserin aut Lei Shu-Hong verfasserin aut In Archives of Biological Sciences University of Belgrade, University of Novi Sad, 2010 65(2013), 3, Seite 1223-1231 (DE-627)538998008 (DE-600)2380842-1 18214339 nnns volume:65 year:2013 number:3 pages:1223-1231 https://doi.org/10.2298/ABS1303223L kostenfrei https://doaj.org/article/cffd23ed4a7547d58c2cebf86370e18c kostenfrei http://www.doiserbia.nb.rs/img/doi/0354-4664/2013/0354-46641303223L.pdf kostenfrei https://doaj.org/toc/0354-4664 Journal toc kostenfrei https://doaj.org/toc/1821-4339 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 65 2013 3 1223-1231
allfieldsGer	10.2298/ABS1303223L doi (DE-627)DOAJ027291898 (DE-599)DOAJcffd23ed4a7547d58c2cebf86370e18c DE-627 ger DE-627 rakwb eng QH301-705.5 Liu Shuang-Qing verfasserin aut Anticoagulant effect of Huisheng Oral Solution in a rat model of thrombosis 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The aim of this study was to investigate whether Huisheng Oral Solution has an anticoagulant effect in a rat model of thrombosis. Forty male SD rats were equally and randomly divided into four groups: blank group, model group, and two treatment groups (A and B). Rats were subcutaneously injected with carrageenan to induce thrombosis. Rats in treatment group A were intragastrically administered with Huisheng Oral Solution in a dose of 2 mL/100 g body weight (once per 8 h) 72 h after carrageenan injection, and those in treatment group B both 72 h before and after the induction of thrombosis. Blood samples were collected 24, 48, and 72 h after carrageenan injection for measurements of prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR), fibrinogen (FIB), prothrombin activity (PTA), platelets (PLT), fibrin degradation products (FDPs), and D-dimer. Lung, liver and mesentery samples were taken 72 h after carrageenan injection for histopathological analysis. The number of microthrombi in sections of different tissue samples were counted under a microscope. Blood parameters among each group were compared using the Welch test, Kruskal-Wallis test or SNK test after testing for normality, while the number of microthrombi was compared using the Bonferroni test. Compared to the model group, PT, APTT, INR, and FIB levels at the majority of time points were significantly shorter or lower in the two treatment groups (P <0.05 for all), but the PTA was not significantly improved in the treatment groups. The levels of FDPs and D-dimer and PLT counts at the majority of time points were significantly lower (P <0.05 for all), and the numbers of microthrombi in the lung, liver and mesentery samples were significantly decreased (P <0.05 for all) in the two treatment groups. The above parameters at the majority of time points showed no significant differences between the two treatment groups. We conclude that Huisheng Oral Solution can significantly improve coagulation parameters, fibrinolysis parameters, and PLT count, and reduce blood hypercoagulability and microthrombosis suggesting that Huisheng Oral Solution has an anticoagulant effect in a rat model of thrombosis. Huisheng Oral Solution hypercoagulable state microthrombus fibrinolysis thrombosis Biology (General) Guo Jiang-Ying verfasserin aut Deng Qun verfasserin aut He Zhong-Jie verfasserin aut Lei Shu-Hong verfasserin aut In Archives of Biological Sciences University of Belgrade, University of Novi Sad, 2010 65(2013), 3, Seite 1223-1231 (DE-627)538998008 (DE-600)2380842-1 18214339 nnns volume:65 year:2013 number:3 pages:1223-1231 https://doi.org/10.2298/ABS1303223L kostenfrei https://doaj.org/article/cffd23ed4a7547d58c2cebf86370e18c kostenfrei http://www.doiserbia.nb.rs/img/doi/0354-4664/2013/0354-46641303223L.pdf kostenfrei https://doaj.org/toc/0354-4664 Journal toc kostenfrei https://doaj.org/toc/1821-4339 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 65 2013 3 1223-1231
allfieldsSound	10.2298/ABS1303223L doi (DE-627)DOAJ027291898 (DE-599)DOAJcffd23ed4a7547d58c2cebf86370e18c DE-627 ger DE-627 rakwb eng QH301-705.5 Liu Shuang-Qing verfasserin aut Anticoagulant effect of Huisheng Oral Solution in a rat model of thrombosis 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The aim of this study was to investigate whether Huisheng Oral Solution has an anticoagulant effect in a rat model of thrombosis. Forty male SD rats were equally and randomly divided into four groups: blank group, model group, and two treatment groups (A and B). Rats were subcutaneously injected with carrageenan to induce thrombosis. Rats in treatment group A were intragastrically administered with Huisheng Oral Solution in a dose of 2 mL/100 g body weight (once per 8 h) 72 h after carrageenan injection, and those in treatment group B both 72 h before and after the induction of thrombosis. Blood samples were collected 24, 48, and 72 h after carrageenan injection for measurements of prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR), fibrinogen (FIB), prothrombin activity (PTA), platelets (PLT), fibrin degradation products (FDPs), and D-dimer. Lung, liver and mesentery samples were taken 72 h after carrageenan injection for histopathological analysis. The number of microthrombi in sections of different tissue samples were counted under a microscope. Blood parameters among each group were compared using the Welch test, Kruskal-Wallis test or SNK test after testing for normality, while the number of microthrombi was compared using the Bonferroni test. Compared to the model group, PT, APTT, INR, and FIB levels at the majority of time points were significantly shorter or lower in the two treatment groups (P <0.05 for all), but the PTA was not significantly improved in the treatment groups. The levels of FDPs and D-dimer and PLT counts at the majority of time points were significantly lower (P <0.05 for all), and the numbers of microthrombi in the lung, liver and mesentery samples were significantly decreased (P <0.05 for all) in the two treatment groups. The above parameters at the majority of time points showed no significant differences between the two treatment groups. We conclude that Huisheng Oral Solution can significantly improve coagulation parameters, fibrinolysis parameters, and PLT count, and reduce blood hypercoagulability and microthrombosis suggesting that Huisheng Oral Solution has an anticoagulant effect in a rat model of thrombosis. Huisheng Oral Solution hypercoagulable state microthrombus fibrinolysis thrombosis Biology (General) Guo Jiang-Ying verfasserin aut Deng Qun verfasserin aut He Zhong-Jie verfasserin aut Lei Shu-Hong verfasserin aut In Archives of Biological Sciences University of Belgrade, University of Novi Sad, 2010 65(2013), 3, Seite 1223-1231 (DE-627)538998008 (DE-600)2380842-1 18214339 nnns volume:65 year:2013 number:3 pages:1223-1231 https://doi.org/10.2298/ABS1303223L kostenfrei https://doaj.org/article/cffd23ed4a7547d58c2cebf86370e18c kostenfrei http://www.doiserbia.nb.rs/img/doi/0354-4664/2013/0354-46641303223L.pdf kostenfrei https://doaj.org/toc/0354-4664 Journal toc kostenfrei https://doaj.org/toc/1821-4339 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 65 2013 3 1223-1231
language	English
source	In Archives of Biological Sciences 65(2013), 3, Seite 1223-1231 volume:65 year:2013 number:3 pages:1223-1231
sourceStr	In Archives of Biological Sciences 65(2013), 3, Seite 1223-1231 volume:65 year:2013 number:3 pages:1223-1231
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Huisheng Oral Solution hypercoagulable state microthrombus fibrinolysis thrombosis Biology (General)
isfreeaccess_bool	true
container_title	Archives of Biological Sciences
authorswithroles_txt_mv	Liu Shuang-Qing @@aut@@ Guo Jiang-Ying @@aut@@ Deng Qun @@aut@@ He Zhong-Jie @@aut@@ Lei Shu-Hong @@aut@@
publishDateDaySort_date	2013-01-01T00:00:00Z
hierarchy_top_id	538998008
id	DOAJ027291898
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ027291898</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307112801.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2013 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2298/ABS1303223L</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ027291898</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJcffd23ed4a7547d58c2cebf86370e18c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QH301-705.5</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Liu Shuang-Qing</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Anticoagulant effect of Huisheng Oral Solution in a rat model of thrombosis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The aim of this study was to investigate whether Huisheng Oral Solution has an anticoagulant effect in a rat model of thrombosis. Forty male SD rats were equally and randomly divided into four groups: blank group, model group, and two treatment groups (A and B). Rats were subcutaneously injected with carrageenan to induce thrombosis. Rats in treatment group A were intragastrically administered with Huisheng Oral Solution in a dose of 2 mL/100 g body weight (once per 8 h) 72 h after carrageenan injection, and those in treatment group B both 72 h before and after the induction of thrombosis. Blood samples were collected 24, 48, and 72 h after carrageenan injection for measurements of prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR), fibrinogen (FIB), prothrombin activity (PTA), platelets (PLT), fibrin degradation products (FDPs), and D-dimer. Lung, liver and mesentery samples were taken 72 h after carrageenan injection for histopathological analysis. The number of microthrombi in sections of different tissue samples were counted under a microscope. Blood parameters among each group were compared using the Welch test, Kruskal-Wallis test or SNK test after testing for normality, while the number of microthrombi was compared using the Bonferroni test. Compared to the model group, PT, APTT, INR, and FIB levels at the majority of time points were significantly shorter or lower in the two treatment groups (P <0.05 for all), but the PTA was not significantly improved in the treatment groups. The levels of FDPs and D-dimer and PLT counts at the majority of time points were significantly lower (P <0.05 for all), and the numbers of microthrombi in the lung, liver and mesentery samples were significantly decreased (P <0.05 for all) in the two treatment groups. The above parameters at the majority of time points showed no significant differences between the two treatment groups. We conclude that Huisheng Oral Solution can significantly improve coagulation parameters, fibrinolysis parameters, and PLT count, and reduce blood hypercoagulability and microthrombosis suggesting that Huisheng Oral Solution has an anticoagulant effect in a rat model of thrombosis.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Huisheng Oral Solution</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hypercoagulable state</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">microthrombus</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fibrinolysis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">thrombosis</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Biology (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Guo Jiang-Ying</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Deng Qun</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">He Zhong-Jie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lei Shu-Hong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Archives of Biological Sciences</subfield><subfield code="d">University of Belgrade, University of Novi Sad, 2010</subfield><subfield code="g">65(2013), 3, Seite 1223-1231</subfield><subfield code="w">(DE-627)538998008</subfield><subfield code="w">(DE-600)2380842-1</subfield><subfield code="x">18214339</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:65</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:1223-1231</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.2298/ABS1303223L</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/cffd23ed4a7547d58c2cebf86370e18c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.doiserbia.nb.rs/img/doi/0354-4664/2013/0354-46641303223L.pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0354-4664</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1821-4339</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">65</subfield><subfield code="j">2013</subfield><subfield code="e">3</subfield><subfield code="h">1223-1231</subfield></datafield></record></collection>
callnumber-first	Q - Science
author	Liu Shuang-Qing
spellingShingle	Liu Shuang-Qing misc QH301-705.5 misc Huisheng Oral Solution misc hypercoagulable state misc microthrombus misc fibrinolysis misc thrombosis misc Biology (General) Anticoagulant effect of Huisheng Oral Solution in a rat model of thrombosis
authorStr	Liu Shuang-Qing
ppnlink_with_tag_str_mv	@@773@@(DE-627)538998008
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	QH301-705
illustrated	Not Illustrated
issn	18214339
topic_title	QH301-705.5 Anticoagulant effect of Huisheng Oral Solution in a rat model of thrombosis Huisheng Oral Solution hypercoagulable state microthrombus fibrinolysis thrombosis
topic	misc QH301-705.5 misc Huisheng Oral Solution misc hypercoagulable state misc microthrombus misc fibrinolysis misc thrombosis misc Biology (General)
topic_unstemmed	misc QH301-705.5 misc Huisheng Oral Solution misc hypercoagulable state misc microthrombus misc fibrinolysis misc thrombosis misc Biology (General)
topic_browse	misc QH301-705.5 misc Huisheng Oral Solution misc hypercoagulable state misc microthrombus misc fibrinolysis misc thrombosis misc Biology (General)
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Archives of Biological Sciences
hierarchy_parent_id	538998008
hierarchy_top_title	Archives of Biological Sciences
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)538998008 (DE-600)2380842-1
title	Anticoagulant effect of Huisheng Oral Solution in a rat model of thrombosis
ctrlnum	(DE-627)DOAJ027291898 (DE-599)DOAJcffd23ed4a7547d58c2cebf86370e18c
title_full	Anticoagulant effect of Huisheng Oral Solution in a rat model of thrombosis
author_sort	Liu Shuang-Qing
journal	Archives of Biological Sciences
journalStr	Archives of Biological Sciences
callnumber-first-code	Q
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2013
contenttype_str_mv	txt
container_start_page	1223
author_browse	Liu Shuang-Qing Guo Jiang-Ying Deng Qun He Zhong-Jie Lei Shu-Hong
container_volume	65
class	QH301-705.5
format_se	Elektronische Aufsätze
author-letter	Liu Shuang-Qing
doi_str_mv	10.2298/ABS1303223L
author2-role	verfasserin
title_sort	anticoagulant effect of huisheng oral solution in a rat model of thrombosis
callnumber	QH301-705.5
title_auth	Anticoagulant effect of Huisheng Oral Solution in a rat model of thrombosis
abstract	The aim of this study was to investigate whether Huisheng Oral Solution has an anticoagulant effect in a rat model of thrombosis. Forty male SD rats were equally and randomly divided into four groups: blank group, model group, and two treatment groups (A and B). Rats were subcutaneously injected with carrageenan to induce thrombosis. Rats in treatment group A were intragastrically administered with Huisheng Oral Solution in a dose of 2 mL/100 g body weight (once per 8 h) 72 h after carrageenan injection, and those in treatment group B both 72 h before and after the induction of thrombosis. Blood samples were collected 24, 48, and 72 h after carrageenan injection for measurements of prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR), fibrinogen (FIB), prothrombin activity (PTA), platelets (PLT), fibrin degradation products (FDPs), and D-dimer. Lung, liver and mesentery samples were taken 72 h after carrageenan injection for histopathological analysis. The number of microthrombi in sections of different tissue samples were counted under a microscope. Blood parameters among each group were compared using the Welch test, Kruskal-Wallis test or SNK test after testing for normality, while the number of microthrombi was compared using the Bonferroni test. Compared to the model group, PT, APTT, INR, and FIB levels at the majority of time points were significantly shorter or lower in the two treatment groups (P <0.05 for all), but the PTA was not significantly improved in the treatment groups. The levels of FDPs and D-dimer and PLT counts at the majority of time points were significantly lower (P <0.05 for all), and the numbers of microthrombi in the lung, liver and mesentery samples were significantly decreased (P <0.05 for all) in the two treatment groups. The above parameters at the majority of time points showed no significant differences between the two treatment groups. We conclude that Huisheng Oral Solution can significantly improve coagulation parameters, fibrinolysis parameters, and PLT count, and reduce blood hypercoagulability and microthrombosis suggesting that Huisheng Oral Solution has an anticoagulant effect in a rat model of thrombosis.
abstractGer	The aim of this study was to investigate whether Huisheng Oral Solution has an anticoagulant effect in a rat model of thrombosis. Forty male SD rats were equally and randomly divided into four groups: blank group, model group, and two treatment groups (A and B). Rats were subcutaneously injected with carrageenan to induce thrombosis. Rats in treatment group A were intragastrically administered with Huisheng Oral Solution in a dose of 2 mL/100 g body weight (once per 8 h) 72 h after carrageenan injection, and those in treatment group B both 72 h before and after the induction of thrombosis. Blood samples were collected 24, 48, and 72 h after carrageenan injection for measurements of prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR), fibrinogen (FIB), prothrombin activity (PTA), platelets (PLT), fibrin degradation products (FDPs), and D-dimer. Lung, liver and mesentery samples were taken 72 h after carrageenan injection for histopathological analysis. The number of microthrombi in sections of different tissue samples were counted under a microscope. Blood parameters among each group were compared using the Welch test, Kruskal-Wallis test or SNK test after testing for normality, while the number of microthrombi was compared using the Bonferroni test. Compared to the model group, PT, APTT, INR, and FIB levels at the majority of time points were significantly shorter or lower in the two treatment groups (P <0.05 for all), but the PTA was not significantly improved in the treatment groups. The levels of FDPs and D-dimer and PLT counts at the majority of time points were significantly lower (P <0.05 for all), and the numbers of microthrombi in the lung, liver and mesentery samples were significantly decreased (P <0.05 for all) in the two treatment groups. The above parameters at the majority of time points showed no significant differences between the two treatment groups. We conclude that Huisheng Oral Solution can significantly improve coagulation parameters, fibrinolysis parameters, and PLT count, and reduce blood hypercoagulability and microthrombosis suggesting that Huisheng Oral Solution has an anticoagulant effect in a rat model of thrombosis.
abstract_unstemmed	The aim of this study was to investigate whether Huisheng Oral Solution has an anticoagulant effect in a rat model of thrombosis. Forty male SD rats were equally and randomly divided into four groups: blank group, model group, and two treatment groups (A and B). Rats were subcutaneously injected with carrageenan to induce thrombosis. Rats in treatment group A were intragastrically administered with Huisheng Oral Solution in a dose of 2 mL/100 g body weight (once per 8 h) 72 h after carrageenan injection, and those in treatment group B both 72 h before and after the induction of thrombosis. Blood samples were collected 24, 48, and 72 h after carrageenan injection for measurements of prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR), fibrinogen (FIB), prothrombin activity (PTA), platelets (PLT), fibrin degradation products (FDPs), and D-dimer. Lung, liver and mesentery samples were taken 72 h after carrageenan injection for histopathological analysis. The number of microthrombi in sections of different tissue samples were counted under a microscope. Blood parameters among each group were compared using the Welch test, Kruskal-Wallis test or SNK test after testing for normality, while the number of microthrombi was compared using the Bonferroni test. Compared to the model group, PT, APTT, INR, and FIB levels at the majority of time points were significantly shorter or lower in the two treatment groups (P <0.05 for all), but the PTA was not significantly improved in the treatment groups. The levels of FDPs and D-dimer and PLT counts at the majority of time points were significantly lower (P <0.05 for all), and the numbers of microthrombi in the lung, liver and mesentery samples were significantly decreased (P <0.05 for all) in the two treatment groups. The above parameters at the majority of time points showed no significant differences between the two treatment groups. We conclude that Huisheng Oral Solution can significantly improve coagulation parameters, fibrinolysis parameters, and PLT count, and reduce blood hypercoagulability and microthrombosis suggesting that Huisheng Oral Solution has an anticoagulant effect in a rat model of thrombosis.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	3
title_short	Anticoagulant effect of Huisheng Oral Solution in a rat model of thrombosis
url	https://doi.org/10.2298/ABS1303223L https://doaj.org/article/cffd23ed4a7547d58c2cebf86370e18c http://www.doiserbia.nb.rs/img/doi/0354-4664/2013/0354-46641303223L.pdf https://doaj.org/toc/0354-4664 https://doaj.org/toc/1821-4339
remote_bool	true
author2	Guo Jiang-Ying Deng Qun He Zhong-Jie Lei Shu-Hong
author2Str	Guo Jiang-Ying Deng Qun He Zhong-Jie Lei Shu-Hong
ppnlink	538998008
callnumber-subject	QH - Natural History and Biology
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.2298/ABS1303223L
callnumber-a	QH301-705.5
up_date	2024-07-04T01:07:02.861Z
_version_	1803608625368793088
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ027291898</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307112801.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2013 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2298/ABS1303223L</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ027291898</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJcffd23ed4a7547d58c2cebf86370e18c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QH301-705.5</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Liu Shuang-Qing</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Anticoagulant effect of Huisheng Oral Solution in a rat model of thrombosis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The aim of this study was to investigate whether Huisheng Oral Solution has an anticoagulant effect in a rat model of thrombosis. Forty male SD rats were equally and randomly divided into four groups: blank group, model group, and two treatment groups (A and B). Rats were subcutaneously injected with carrageenan to induce thrombosis. Rats in treatment group A were intragastrically administered with Huisheng Oral Solution in a dose of 2 mL/100 g body weight (once per 8 h) 72 h after carrageenan injection, and those in treatment group B both 72 h before and after the induction of thrombosis. Blood samples were collected 24, 48, and 72 h after carrageenan injection for measurements of prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR), fibrinogen (FIB), prothrombin activity (PTA), platelets (PLT), fibrin degradation products (FDPs), and D-dimer. Lung, liver and mesentery samples were taken 72 h after carrageenan injection for histopathological analysis. The number of microthrombi in sections of different tissue samples were counted under a microscope. Blood parameters among each group were compared using the Welch test, Kruskal-Wallis test or SNK test after testing for normality, while the number of microthrombi was compared using the Bonferroni test. Compared to the model group, PT, APTT, INR, and FIB levels at the majority of time points were significantly shorter or lower in the two treatment groups (P <0.05 for all), but the PTA was not significantly improved in the treatment groups. The levels of FDPs and D-dimer and PLT counts at the majority of time points were significantly lower (P <0.05 for all), and the numbers of microthrombi in the lung, liver and mesentery samples were significantly decreased (P <0.05 for all) in the two treatment groups. The above parameters at the majority of time points showed no significant differences between the two treatment groups. We conclude that Huisheng Oral Solution can significantly improve coagulation parameters, fibrinolysis parameters, and PLT count, and reduce blood hypercoagulability and microthrombosis suggesting that Huisheng Oral Solution has an anticoagulant effect in a rat model of thrombosis.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Huisheng Oral Solution</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hypercoagulable state</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">microthrombus</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fibrinolysis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">thrombosis</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Biology (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Guo Jiang-Ying</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Deng Qun</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">He Zhong-Jie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lei Shu-Hong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Archives of Biological Sciences</subfield><subfield code="d">University of Belgrade, University of Novi Sad, 2010</subfield><subfield code="g">65(2013), 3, Seite 1223-1231</subfield><subfield code="w">(DE-627)538998008</subfield><subfield code="w">(DE-600)2380842-1</subfield><subfield code="x">18214339</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:65</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:1223-1231</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.2298/ABS1303223L</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/cffd23ed4a7547d58c2cebf86370e18c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.doiserbia.nb.rs/img/doi/0354-4664/2013/0354-46641303223L.pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0354-4664</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1821-4339</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">65</subfield><subfield code="j">2013</subfield><subfield code="e">3</subfield><subfield code="h">1223-1231</subfield></datafield></record></collection>
score	7.4003057

Nicht das Richtige dabei?

Schreiben Sie uns!

Anticoagulant effect of Huisheng Oral Solution in a rat model of thrombosis

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?